Related Experiment Video

Updated: May 21, 2026

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins
08:12

Utilizing a Comprehensive Immunoprecipitation Enrichment System to Identify an Endogenous Post-translational Modification Profile for Target Proteins

Published on: January 8, 2018

Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from

Kai-Qiang Li1, Si-Qi Ding1, Yun Lei1

  • 1Department of Surgical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China.

NPJ Precision Oncology
|May 19, 2026
PubMed

Insights

Post-translational modifications (PTMs) like ubiquitination dynamically regulate the tumor microenvironment and cancer immunity. Targeting these PTMs offers new strategies to overcome immunotherapy resistance and improve cancer treatments.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • The tumor microenvironment (TME) is crucial for cancer immunity.
  • Complex post-translational modifications (PTMs) dynamically regulate TME functions.
  • Ubiquitination and other PTMs are key regulators of immune responses in cancer.

Purpose of the Study:

  • To review the intricate crosstalk between ubiquitination and other PTMs in cancer immunity.
  • To highlight the role of PTMs in regulating immune checkpoint activity and immune cell function.
  • To summarize therapeutic strategies targeting PTMs for cancer immunotherapy.

Main Methods:

  • Literature review of studies on PTMs in cancer immunity.
  • Analysis of regulatory mechanisms of PTMs on immune checkpoints (e.g., PD-L1).
  • Examination of PTMs' impact on immune cell function and signaling pathways.

Main Results:

  • PTMs, including ubiquitination, phosphorylation, glycosylation, and acetylation, orchestrate immune checkpoint activity and immune cell function.
  • The stability and function of immune checkpoint proteins are dynamically regulated by synergistic or competitive PTMs.
  • PTMs influence T cells, NK cells, macrophages, and signaling pathways like STAT, type I IFN, and NF-κB.

Conclusions:

  • Targeting PTMs offers promising therapeutic strategies, including small-molecule inhibitors and novel technologies like PROTACs.
  • Understanding PTM crosstalk is essential for overcoming immunotherapy resistance and optimizing combination therapies.
  • Future research should explore non-classical PTMs and multi-omics approaches for precision immunotherapy.

More Related Videos

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model09:00

Comparative Strategies for Ubiquitination Detection in Mammalian Cell Lysates Using SMAD2/SMURF2 as a Model

Published on: April 17, 2026

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations10:26

Profiling Ubiquitin and Ubiquitin-like Dependent Post-translational Modifications and Identification of Significant Alterations

Published on: November 7, 2019

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein.
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...